About Inimmune
Inimmune is a company based in Missoula (United States) founded in 2016 by Kendal Ryter. Inimmune has raised $22 million across 3 funding rounds from investors including NIH, HHS and Two Bear Capital. The company has 35 employees as of December 31, 2021. Inimmune offers products and services including INI-2004, INI-4001, and TRAC478. Inimmune operates in a competitive market with competitors including BeiGene, Serum Institute of India, TScan Therapeutics, Vir Biotechnology and BioNTech, among others.
- Headquarter Missoula, United States
- Employees 35 as on 31 Dec, 2021
- Founders Kendal Ryter
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Inimmune Corp.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$22 M (USD)
in 3 rounds
-
Latest Funding Round
$22 M (USD), Series A
Jul 10, 2020
-
Investors
NIH
& 2 more
-
Employee Count
35
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inimmune
Inimmune offers a comprehensive portfolio of products and services, including INI-2004, INI-4001, and TRAC478.
TLR4 agonist for treating allergic rhinitis in clinical trials
TLR7/8 agonist for cancer treatment with checkpoint inhibitors
Adjuvant system for enhancing vaccine responses
People of Inimmune
Unlock access to complete
Unlock access to complete
Funding Insights of Inimmune
Inimmune has successfully raised a total of $22M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $22 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inimmune
Inimmune has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Two Bear Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Two Bear Capital is focused on investing in innovative founders.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Inimmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inimmune
Investment portfolio details for Inimmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inimmune
Detailed financials for Inimmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inimmune Comparisons
Peer comparison for Inimmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inimmune
Inimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, TScan Therapeutics, Vir Biotechnology and BioNTech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare respiratory diseases are developed by Savara Pharma.
|
Detailed competitors of Inimmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inimmune
Complete news archive for Inimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inimmune
Inimmune was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Inimmune is headquartered in Missoula, United States. It is registered at Missoula, Montana, United States.
Inimmune is a funded company, having raised a total of $22M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Inimmune is 35.
Inimmune was founded in 2016 in Missoula, United States, within the biotechnology sector. Focus is placed on discovering and developing innate immune receptor agonists and antagonists to address food allergies, allergic rhinitis, and autoimmune disorders. The pipeline encompasses preclinical vaccines for food allergies, modulators for rhinitis, and discovery-stage TLR antagonists for Th1Th2Th17-mediated conditions. Fee-based contract services, including drug formulation, analytical chemistry, immunology, and chemical synthesis, are offered to pharmaceutical partners.
Inimmune offers INI-2004, INI-4001, and TRAC478.
Inimmune has 3 investors. Key investors include NIH, HHS, and Two Bear Capital.